Ignite Creation Date:
2024-05-06 @ 8:11 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06280482
Status:
RECRUITING
Last Update Posted:
2024-04-05
First Post:
2024-02-19
Brief Title:
Nicotinamide Riboside NR to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome SMDS
Sponsor:
The University of Texas Health Science Center Houston
Organization:
The University of Texas Health Science Center Houston
Study Overview
Official Title:
Nicotinamide Riboside NR to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome SMDS
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether SMDS patients treated with NR at the proposed dose exhibit decreased glucose uptake in the aorta to determine if NR treatment results in measurable changes of blood NAD and NR levels to determine if aortic measurements are stable after treatment with NR and to evaluate the safety and tolerability of NR in SMDS patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None